Allopurinol and ellagic acid decrease epileptiform activity and the severity of convulsive behavior in a model of
Kenia Pardo-Peña1, Laura Medina-Ceja, Salvador Martínez-Gallegos
1Department of Cellular and Molecular Biology, Laboratory of Neurophysiology, University of Guadalajara, Zapopan, Jalisco, México.
Neuroreport
|January 6, 2023
Summary
Antioxidants allopurinol and ellagic acid effectively reduced seizure activity and severity during status epilepticus. Pretreatment with these agents offered greater protection against seizures and associated neuronal damage.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Status epilepticus involves severe seizures, leading to excitotoxicity and oxidative stress, causing neuronal damage.
- Antioxidant agents offer a potential therapeutic strategy to mitigate seizure severity and neurobiological consequences.
Purpose of the Study:
- To evaluate the antiseizure effects of allopurinol (ALL) and ellagic acid during pilocarpine-induced status epilepticus.
- To assess the impact of these antioxidants on epileptiform activity and convulsive behavior.
Main Methods:
- Male Wistar rats were administered allopurinol or ellagic acid (50 mg/kg) either 30 minutes before or 60 minutes after pilocarpine-induced status epilepticus.
- Evaluated antiseizure effects on epileptiform activity and convulsive behavior.
Main Results:
- Both allopurinol and ellagic acid significantly reduced epileptiform activity and convulsive behavior severity.
- Pretreatment demonstrated superior efficacy, increasing seizure latency and significantly reducing discharge amplitude (ALL: 53.5%, ellagic acid: 68.9%).
Conclusions:
- Allopurinol and ellagic acid exhibit significant antiseizure effects.
- These antioxidants can serve as adjunctive therapies to reduce seizure activity and oxidative damage in status epilepticus.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
241
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
241
01:20Antiepileptic Drugs: Potassium Channel Activators
242
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
242
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
512
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
512
01:14Antiepileptic Drugs: Glutamate Antagonists
472
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
472
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
397
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
397
01:17Antiepileptic Drugs: Calcium Channel Blockers
526
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
526